BI Asset Management Fondsmaeglerselskab A S Sells 9,483 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

BI Asset Management Fondsmaeglerselskab A S reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 36.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,508 shares of the company's stock after selling 9,483 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in IDEXX Laboratories were worth $6,825,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $41,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Up 3.4 %

Shares of IDEXX Laboratories stock traded up $14.35 on Thursday, reaching $440.98. 746,755 shares of the company's stock were exchanged, compared to its average volume of 629,776. The firm's 50-day moving average is $420.23 and its two-hundred day moving average is $429.89. The company has a market capitalization of $35.74 billion, a P/E ratio of 41.33, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IDXX. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $523.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.